ReviewDiabetes2025
New Insights Into Diabetes-Induced Cell-Type-Specific Responses in the Neural Retina via Single-Cell Transcriptomics: A Report on Research Supported by Pathway to Stop Diabetes.
Review in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Super-resolution ultrasound microscopy profiles microvasculomics of pancreatic ductal adenocarcinoma with pathological association and facilitates differential diagnosis.La Radiologia medica · 2026Article
- Crosstalk between endoplasmic reticulum stress and mitochondrial homeostasis: A new perspective on ophthalmic disease treatment.Journal of cell communication and signaling · 2026Review
- Mechanisms and applications of natural plant ingredients in modulating amino acid metabolism for the improvement of diabetic retinopathy: a review.Frontiers in endocrinology · 2026Review
- Exerkines in diabetic retinopathy: from mechanisms to therapeutic prospects.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diabetes triggers cell-type-specific responses in the retina, leading to vascular lesions, glial dysfunction, and neurodegeneration, all of which contribute to the progression of diabetic retinopathy (DR). However, the specific cell types involved in disease development and the molecular mechanisms driving their responses have not yet been fully clarified, impeding the creation of effective therapeutic strategies. Recent advancements in single-cell or single-nuclei transcriptomic technologies have provided a systematic approach to profile transcript-level alterations at single-cell resolution, allowing for an in-depth analysis of diabetes-induced retinal transcriptional changes across various animal models for DR. Here, in the context of research funded by the American Diabetes Association Pathway to Stop Diabetes program, we discuss the cell-type-specific responses in the neural retina identified through single-cell transcriptomic analyses. We emphasize new insights into neural retinal responses, potential therapeutic targets, and the limitations and unresolved topics that warrant further investigation. This article is part of a series of perspectives that report on research funded by the American Diabetes Association Pathway to Stop Diabetes program. ARTICLE HIGHLIGHTS: Single-cell transcriptomics provides a powerful solution for dissecting diabetes-induced cell-type-specific responses in mammalian retina. This article summarizes key findings from recent single-cell transcriptomic studies regarding the mechanisms of diabetic retinopathy, with a particular emphasis on the neural retina. Specific retinal neuronal types/subtypes exhibit heightened sensitivity to diabetes at the transcriptional level. Retinal Müller glial cells are key contributors to diabetic retinopathy and promising therapeutic targets for retinal protection against diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.